Enable Injections welcomes Nigel Sheail to its Board of Directors

– USA, OH –  Enable Injections, Inc., a company developing and manufacturing the enFuse platform of investigational wearable drug delivery systems, today announced the appointment of Nigel Sheail to its Board of Directors, effective October 27, 2022, increasing the Board to nine members adding meaningful operating, investing, pharmaceutical, and delivery systems experience.

“We are delighted to welcome Nigel as a new director to Enable’s Board. His business experience with global pharmaceutical companies brings new perspectives and skills which will be critical as we grow our business into a major player in the healthcare and drug delivery industry,” said Chairman and CEO, Mike Hooven.

About Nigel Sheail

Nigel Sheail brings over two decades of expertise as a global biopharma executive, most recently at Novartis as the Global Head of Mergers & Acquisitions and Business Development & Licensing. Before Novartis, Nigel worked at Bayer Healthcare AG, F Hoffmann-La Roche Ltd., and GSK.

“Enable Injections’ innovative delivery technology, enFuse, has the potential to positively impact the patient experience and support healthcare providers to optimize their practice,” said Nigel Sheail. “I look forward to working with the Enable Injections management team and Board at this exciting time in the company’s development.”

About Enable Injections

Cincinnati-based Enable Injections is a global healthcare innovation company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable’s body-worn enFuse delivers high-volume pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. The investigational enFuse system has not been approved by any regulatory agency and is currently not approved for commercial use.

Enable Injections’ enFuse is a hands-free, hidden needle, large-volume drug delivery technology designed to deliver therapeutics subcutaneously via constant pressure.

For more information: https://enableinjections.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.